Jump to content

Sprifermin

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 11:02, 3 June 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sprifermin is another name for human recombinant FGF18. Its manufacturers hope it will soon enter clinical trials for treatment of knee osteoarthritis.[1]

References

  1. ^ "Merck Announces Collaboration With Nordic Bioscience for Sprifermin in Osteoarthritis of the Knee". Merck Group. 18 March 2013. Retrieved 30 May 2013.